{"nctId":"NCT00877877","briefTitle":"Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects.","startDateStruct":{"date":"2009-05-07","type":"ACTUAL"},"conditions":["Infections, Papillomavirus","Papillomavirus Vaccines"],"count":632,"armGroups":[{"label":"Cervarix Group","type":"OTHER","interventionNames":["Procedure: Blood sampling"]}],"interventions":[{"name":"Blood sampling","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects who the investigator believes that they and/or their parents or legally acceptable representative (LAR) can and will comply with the requirements of the protocol should be enrolled in the study.\n* A female enrolled in the immunogenicity subset of study 580299-013, who received three doses of HPV vaccine and participated in the extension study of 580299-013.\n* Written informed assent obtained from the subject. For subjects below the legal age of consent, written informed consent must be obtained from a parent or legally acceptable representative of the subject.\n\nExclusion Criteria:\n\n* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.\n* Use of any investigational or non-registered product (drug or vaccine) or planned use during the study period.\n* Administration or planned administration of any HPV vaccine, other than the vaccine administered in study 580299-013.\n* Chronic administration of immunosuppressants or other immune-modifying drugs occurring within the three months preceding study entry.\n* Administration of immunoglobulins and/or any blood products occurring within the three months preceding study entry.","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"15 Years","maximumAge":"24 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Seroconverted Subjects With Anti-HPV-16/18 Antibody Titers Equal to or Above Cut-off Values.","description":"Anti-HPV-16 assay cut-off value was defined as 8 ELISA units per milliliter (EL.U/mL). Anti-HPV-18 assay cut-off value was defined as 7 EL.U/mL.\n\nSeroconversion was defined as the appearance of antibodies (i.e. titer greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination.\n\nA seronegative subject is a subject with antibody titer \\< 8 or 7 EL.U/mL prior to vaccination.\n\nA seropositive subject is a subject with antibody titer \\>= 8 or 7 EL.U/mL prior to vaccination.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"353","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"358","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Seroconverted Subjects With Anti-HPV-16/18 Antibody Titers Equal to or Above Cut-off Values.","description":"Anti-HPV-16 assay cut-off value was defined as 8 ELISA units per milliliter (EL.U/mL). Anti-HPV-18 assay cut-off value was defined as 7 EL.U/mL.\n\nSeroconversion was defined as the appearance of antibodies (i.e. titer greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination.\n\nA seronegative subject is a subject with antibody titer \\< 8 or 7 EL.U/mL prior to vaccination.\n\nA seropositive subject is a subject with antibody titer \\>= 8 or 7 EL.U/mL prior to vaccination.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"475","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"478","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Seroconverted Subjects With Anti-HPV-16/18 Antibody Titers Equal to or Above Cut-off Values.","description":"Anti-HPV-16 assay cut-off value was defined as 8 ELISA units per milliliter (EL.U/mL). Anti-HPV-18 assay cut-off value was defined as 7 EL.U/mL.\n\nSeroconversion was defined as the appearance of antibodies (i.e. titer greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination.\n\nA seronegative subject is a subject with antibody titer \\< 8 or 7 EL.U/mL prior to vaccination.\n\nA seropositive subject is a subject with antibody titer \\>= 8 or 7 EL.U/mL prior to vaccination.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"469","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"473","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Seroconverted Subjects With Anti-HPV-16/18 Antibody Titers Equal to or Above Cut-off Values.","description":"Anti-HPV-16 assay cut-off value was defined as 8 ELISA units per milliliter (EL.U/mL). Anti-HPV-18 assay cut-off value was defined as 7 EL.U/mL.\n\nSeroconversion was defined as the appearance of antibodies (i.e. titer greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination.\n\nA seronegative subject is a subject with antibody titer \\< 8 or 7 EL.U/mL prior to vaccination.\n\nA seropositive subject is a subject with antibody titer \\>= 8 or 7 EL.U/mL prior to vaccination.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"473","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"477","spread":null}]}]}]},{"type":"PRIMARY","title":"Anti-human Papillomavirus-16 and 18 (Anti-HPV-16/18) Antibody Titers","description":"Anti-HPV-16 and 18 antibody titers are given in Geometric Mean Titers (GMTs) in Enzyme-linked Immunosorbent Assay (ELISA) Units per milliliter (EL.U/mL).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2262.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"778.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Anti-human Papillomavirus-16 and 18 (Anti-HPV-16/18) Antibody Titers","description":"Anti-HPV-16 and 18 antibody titers are given in Geometric Mean Titers (GMTs) in Enzyme-linked Immunosorbent Assay (ELISA) Units per milliliter (EL.U/mL).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1973.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"762.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Anti-human Papillomavirus-16 and 18 (Anti-HPV-16/18) Antibody Titers","description":"Anti-HPV-16 and 18 antibody titers are given in Geometric Mean Titers (GMTs) in Enzyme-linked Immunosorbent Assay (ELISA) Units per milliliter (EL.U/mL).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1756.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"609.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Anti-human Papillomavirus-16 and 18 (Anti-HPV-16/18) Antibody Titers","description":"Anti-HPV-16 and 18 antibody titers are given in Geometric Mean Titers (GMTs) in Enzyme-linked Immunosorbent Assay (ELISA) Units per milliliter (EL.U/mL).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1671.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"679.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Seroconverted Subjects With Anti-HPV-16/18 Antibody Titers Equal to or Above Cut-off Values.","description":"Anti-HPV-16 assay cut-off value was defined as 8 ELISA units per milliliter (EL.U/mL). Anti-HPV-18 assay cut-off value was defined as 7 EL.U/mL. Seroconversion was defined as the appearance of antibodies (i.e. titer greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination. A seronegative subject is a subject with antibody titer \\< 8 or 7 EL.U/mL prior to vaccination. A seropositive subject is a subject with antibody titer \\>= 8 or 7 EL.U/mL prior to vaccination.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"372","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"368","spread":null}]}]}]},{"type":"PRIMARY","title":"Anti-human Papillomavirus-16 and 18 (Anti-HPV-16/18) Antibody Titers","description":"Anti-HPV-16 and 18 antibody titers are given in Geometric Mean Titers (GMTs) in Enzyme-linked Immunosorbent Assay (ELISA) Units per milliliter (EL.U/mL).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1946.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"754.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Anti-human Papillomavirus-16 and 18 (Anti-HPV-16/18) Antibody Titers","description":"Anti-HPV-16 assay cut-off value was defined as 8 ELISA units per milliliter (EL.U/mL). Anti-HPV-18 assay cut-off value was defined as 7 EL.U/mL. Seroconversion was defined as the appearance of antibodies (i.e. titer greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination. A seronegative subject is a subject with antibody titer \\< 8 or 7 EL.U/mL prior to vaccination. A seropositive subject is a subject with antibody titer \\>= 8 or 7 EL.U/mL prior to vaccination.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1607.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"608","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Seroconverted Subjects With Anti-HPV-16/18 Antibody Titers Equal to or Above Cut-off Values.","description":"Anti-HPV-16 assay cut-off value was defined as 8 ELISA units per milliliter (EL.U/mL). Anti-HPV-18 assay cut-off value was defined as 7 EL.U/mL. Seroconversion was defined as the appearance of antibodies (i.e. titer greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination. A seronegative subject is a subject with antibody titer \\< 8 or 7 EL.U/mL prior to vaccination. A seropositive subject is a subject with antibody titer \\>= 8 or 7 EL.U/mL prior to vaccination.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"393","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"395","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Serious Adverse Events (SAEs)","description":"SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Serious Adverse Events (SAEs)","description":"SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Serious Adverse Events (SAEs)","description":"SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Serious Adverse Events (SAEs)","description":"SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Serious Adverse Events (SAEs)","description":"SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Serious Adverse Events (SAEs)","description":"SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":397},"commonTop":[]}}}